Literature DB >> 12954518

Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety.

Carolyn Westhoff1.   

Abstract

Depot-medroxyprogesterone acetate (Depo-Provera(R)) is a highly effective, nondaily hormonal contraceptive option that has been available in the United States for a decade, and worldwide for 40 years. Benefits and risks of hormonal therapy are often under scrutiny; however, long-term clinical experience has established the safety of this long-acting contraceptive. This article reviews the contraceptive efficacy, potential noncontraceptive health benefits and long-term safety of with regard to risk of cardiovascular events, breast and gynecologic malignancy and osteopenia. Comparisons with other hormonal contraceptives are made as clinically appropriate. Common patient management issues, including effects on menstrual cycle, body weight and mood, are also addressed. Finally, this review provides recommendations for appropriate patient selection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954518     DOI: 10.1016/s0010-7824(03)00136-7

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  14 in total

1.  Associations between recent contraceptive use and quality of life among women.

Authors:  Sanithia L Williams; Sara M Parisi; Rachel Hess; E Bimla Schwarz
Journal:  Contraception       Date:  2011-09-19       Impact factor: 3.375

2.  Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes.

Authors:  Jiang-Wei Zhang; Yong Liu; Wei Li; Da-Cheng Hao; Ling Yang
Journal:  Eur J Clin Pharmacol       Date:  2006-04-28       Impact factor: 2.953

3.  The influence of hormonal contraception on mood and sexual interest among adolescents.

Authors:  Mary A Ott; Marcia L Shew; Susan Ofner; Wanzhu Tu; J Dennis Fortenberry
Journal:  Arch Sex Behav       Date:  2008-02-21

Review 4.  Hormonal contraception in adolescents: special considerations.

Authors:  Rollyn M Ornstein; Martin M Fisher
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills.

Authors:  Abbey B Berenson; Susan D Odom; Carmen Radecki Breitkopf; Mahbubur Rahman
Journal:  Am J Obstet Gynecol       Date:  2008-07-03       Impact factor: 8.661

6.  Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health.

Authors:  Opeyemi O Babatunde; Jacky J Forsyth
Journal:  J Bone Miner Metab       Date:  2013-08-07       Impact factor: 2.626

Review 7.  Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.

Authors:  Andrew Owen; Steve Rannard
Journal:  Adv Drug Deliv Rev       Date:  2016-02-23       Impact factor: 15.470

8.  A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.

Authors:  Morgan M Philbin; Carrigan Parish; Sadie Bergen; Deanna Kerrigan; Elizabeth N Kinnard; Sarah E Reed; Mardge H Cohen; Oluwakemi Sosanya; Anandi N Sheth; Adaora A Adimora; Jennifer Cocohoba; Lakshmi Goparaju; Elizabeth T Golub; Margaret Fischl; Maria L Alcaide; Lisa R Metsch
Journal:  AIDS Patient Care STDS       Date:  2021-01       Impact factor: 5.078

Review 9.  Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Authors:  Antoinette G Nelson; Xiaoping Zhang; Usha Ganapathi; Zoltan Szekely; Charles W Flexner; Andrew Owen; Patrick J Sinko
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

Review 10.  Long-acting injectable antiretrovirals for HIV treatment and prevention.

Authors:  William R Spreen; David A Margolis; John C Pottage
Journal:  Curr Opin HIV AIDS       Date:  2013-11       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.